Literature DB >> 27987343

Mature cystic teratoma coexisting with clear-cell carcinoma in the ovary.

Koki Shimura1, Mariko Matsumoto1, Takuya Sugahara1, Takuro Yamamoto1, Nozomi Ogiso1, Yoji Urata1, Tomoharu Okubo1.   

Abstract

Mature cystic teratoma (MCT) is the most common benign ovarian tumor; clear-cell carcinoma (CCC) is a relatively common malignant ovarian tumor in Japan, but there are few reports on the coexistence of MCT and CCC. Here we report a case of simultaneous MCT and CCC in the ovary and review the relevant literature. The patient was a 49-year-old woman. A 5-cm MCT was found in the left ovary on initial gynecological examination, and she was referred to hospital for treatment because it was expanding. Magnetic resonance imaging showed a multilocular cystic tumor 16 × 10 × 9.5 cm in the left ovary, and surgery was performed. The final pathological diagnosis was MCT, endometriotic cyst, clear-cell adenofibroma, clear-cell borderline tumor, and CCC in the left ovary.
© 2016 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  clear-cell adenofibroma; clear-cell borderline tumor; clear-cell carcinoma; endometriotic cyst; mature cystic teratoma

Mesh:

Year:  2016        PMID: 27987343     DOI: 10.1111/jog.13224

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  2 in total

1.  A case of ovarian clear cell carcinoma arising from ovarian mature cystic teratoma.

Authors:  Kazuya Maeda; Yoshito Terai; Shinichi Terada; Hiroshi Maruoka; Yuhei Kogata; Keisuke Ashihara; Yoshimichi Tanaka; Tomohito Tanaka; Hiroshi Sasaki; Satoshi Tsunetoh; Takashi Yamada; Masahide Ohmichi
Journal:  J Ovarian Res       Date:  2018-08-30       Impact factor: 4.234

2.  Luteolin Suppresses Teratoma Cell Growth and Induces Cell Apoptosis via Inhibiting Bcl-2.

Authors:  Teng Liu; Juan Xu; Hong Li Yan; Feng Chun Cheng; Xi Jie Liu
Journal:  Oncol Res       Date:  2018-03-14       Impact factor: 5.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.